GlassScriptPhysician profile
Sherrita Carter
NPI 1639521925
$5,566.59
in general payments reported to CMS, 2019-2025
29 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,779 · 2022: $1,034 · 2023: $1,468 · 2024: $814 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,725.78 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,143.06 | 2021-2025 | Proclaim, Octrode, Infinity |
| Abbvie INC. | $1,013.05 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $415.54 | 2021-2024 | Belbuca, Xtampza |
| Biohaven Pharmaceuticals, INC. | $282.54 | 2021 | |
| Pfizer INC. | $258.22 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $239.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.18 | 2022-2023 | Relistor |
| Spr Therapeutics, INC | $134.55 | 2023 | Sprint Pns System |
| Amgen INC. | $122.70 | 2021 | |
| Medtronic, INC. | $114.92 | 2022-2024 | Synchromedii |
| Vertex Pharmaceuticals Incorporated | $68.85 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $67.28 | 2021-2022 | |
| Ibsa Pharma INC. | $67.15 | 2021-2023 | Tirosint, Licart |
| Grt US Holding, INC. | $57.56 | 2021-2022 | |
| Protega Pharmaceutials INC | $53.30 | 2025 | Roxybond |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $39.67 | 2024 | Durolane |
| Redhill Biopharma INC. | $38.70 | 2021-2022 | |
| Forte Bio-Pharma LLC | $36.27 | 2021 | |
| Lilly USA, LLC | $34.19 | 2021 | |
| Biodelivery Sciences International, INC. | $31.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $26.54 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $25.60 | 2023 | |
| Upsher-Smith Laboratories LLC | $20.24 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.04 | 2021 | |
| Nalu Medical, INC. | $17.86 | 2023 | Nalu Neurostimulation System |
| Baudax Bio INC. | $17.34 | 2022 | |
| Valinor Pharma, LLC | $17.31 | 2025 | Movantik |
| Scilex Pharmaceuticals INC. | $14.02 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherrita Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.